JP2001524928A - クロスプライミング免疫による天然抗原に特異性を有するｃｔｌの誘導 - Google Patents

クロスプライミング免疫による天然抗原に特異性を有するｃｔｌの誘導

Info

Publication number
JP2001524928A
JP2001524928A JP50415598A JP50415598A JP2001524928A JP 2001524928 A JP2001524928 A JP 2001524928A JP 50415598 A JP50415598 A JP 50415598A JP 50415598 A JP50415598 A JP 50415598A JP 2001524928 A JP2001524928 A JP 2001524928A
Authority
JP
Japan
Prior art keywords
tumor
artificial target
antigen
cells
tumor cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP50415598A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001524928A5 (enExample
Inventor
ディー．，ジュニア ファロ，ルイス
エル． ロック，ケネス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pittsburgh
Original Assignee
University of Pittsburgh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Pittsburgh filed Critical University of Pittsburgh
Publication of JP2001524928A publication Critical patent/JP2001524928A/ja
Publication of JP2001524928A5 publication Critical patent/JP2001524928A5/ja
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001148—Regulators of development
    • A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
    • A61K39/001151—Apoptosis related proteins, e.g. survivin or livin p53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00118—Cancer antigens from embryonic or fetal origin
    • A61K39/001182—Carcinoembryonic antigen [CEA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001186—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00119—Melanoma antigens
    • A61K39/001191—Melan-A/MART
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00119—Melanoma antigens
    • A61K39/001192—Glycoprotein 100 [Gp100]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pregnancy & Childbirth (AREA)
  • Developmental Biology & Embryology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
JP50415598A 1996-06-28 1997-06-18 クロスプライミング免疫による天然抗原に特異性を有するｃｔｌの誘導 Ceased JP2001524928A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/675,332 US5951975A (en) 1996-06-28 1996-06-28 Induction of CTLs specific for natural antigens by cross priming immunization
US08/675,332 1996-06-28
PCT/US1997/010195 WO1998000163A1 (en) 1996-06-28 1997-06-18 INDUCTION OF CTLs SPECIFIC FOR NATURAL ANTIGENS BY CROSS-PRIMING IMMUNIZATION

Publications (2)

Publication Number Publication Date
JP2001524928A true JP2001524928A (ja) 2001-12-04
JP2001524928A5 JP2001524928A5 (enExample) 2005-03-10

Family

ID=24710012

Family Applications (1)

Application Number Title Priority Date Filing Date
JP50415598A Ceased JP2001524928A (ja) 1996-06-28 1997-06-18 クロスプライミング免疫による天然抗原に特異性を有するｃｔｌの誘導

Country Status (7)

Country Link
US (1) US5951975A (enExample)
EP (1) EP1007087A1 (enExample)
JP (1) JP2001524928A (enExample)
AU (1) AU724546B2 (enExample)
CA (1) CA2258840A1 (enExample)
IL (1) IL127661A (enExample)
WO (1) WO1998000163A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021029424A1 (ja) * 2019-08-13 2021-02-18 国立研究開発法人医薬基盤・健康・栄養研究所 免疫記憶に基づく新規疾患治療および予防

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6994851B1 (en) * 1997-07-10 2006-02-07 Mannkind Corporation Method of inducing a CTL response
US6977074B2 (en) 1997-07-10 2005-12-20 Mannkind Corporation Method of inducing a CTL response
WO1999051263A2 (en) * 1998-04-08 1999-10-14 University Of North Carolina At Chapel Hill Methods and modified cells for the treatment of cancer
US6844188B1 (en) 1998-04-08 2005-01-18 University Of North Carolina At Chapel Hill Methods and modified cells for the treatment of cancer
US7935805B1 (en) * 1998-12-31 2011-05-03 Novartis Vaccines & Diagnostics, Inc Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
PT1141315E (pt) 1998-12-31 2008-05-05 Novartis Vaccines & Diagnostic Polipéptidos do envelope (env) de hiv modificados
EP1980617A1 (en) * 1998-12-31 2008-10-15 Novartis Vaccines and Diagnostics, Inc. Improved expression of HIV polypeptides and production of virus-like particles
WO2000039304A2 (en) * 1998-12-31 2000-07-06 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
US8128922B2 (en) 1999-10-20 2012-03-06 Johns Hopkins University Superior molecular vaccine linking the translocation domain of a bacterial toxin to an antigen
US7342002B2 (en) * 2000-08-03 2008-03-11 The Johns Hopkins University Molecular vaccine linking an endoplasmic chaperone polypeptide to an antigen
GB0026812D0 (en) * 2000-11-02 2000-12-20 Isis Innovation Cancer therapy
NZ530635A (en) * 2001-06-15 2007-03-30 Nordic Vaccine Technology As Therapeutical vaccination comprising an immunogen and a targeting vehicle comprising a carrier and a antigen silmilar to the first
AU2002320314A1 (en) * 2001-07-05 2003-01-21 Chiron, Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
JP4302513B2 (ja) * 2001-07-05 2009-07-29 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 抗原性ｂ型ｈｉｖポリペプチドおよび／または抗原性ｃ型ｈｉｖポリペプチドをコードするポリヌクレオチド、それらのポリペプチドおよびそれらの使用
US20030170614A1 (en) * 2001-08-31 2003-09-11 Megede Jan Zur Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
JP2005521380A (ja) * 2001-08-31 2005-07-21 カイロン コーポレイション 抗原性ｂ型ｈｉｖポリペプチドをコードするポリヌクレオチド、そのポリペプチドおよびそれらの使用
ES2456666T3 (es) * 2003-04-18 2014-04-23 Biotech Synergy, Inc. Péptidos antígenos HLA-A2 asociados a un tumor y composiciones
WO2004098526A2 (en) * 2003-05-05 2004-11-18 Johns Hopkins University Anti-cancer dna vaccine employing plasmids encoding signal sequence, mutant oncoprotein antigen, and heat shock protein
WO2004100984A1 (en) * 2003-05-13 2004-11-25 The University Of Massachusetts Endogenous adjuvant molecules and uses thereof
WO2006085983A2 (en) * 2004-07-09 2006-08-17 University Of North Carolina At Chapel Hill Viral adjuvants
CA2594040A1 (en) * 2005-01-06 2006-07-13 The Johns Hopkins University Rna interference that blocks expression of pro-apoptotic proteins potentiates immunity induced by dna and transfected dendritic cell vaccines
CA2595726A1 (en) * 2005-01-26 2006-08-03 The Johns Hopkins University Anti-cancer dna vaccine employing plasmids encoding mutant oncoprotein antigen and calreticulin
AU2006302794B2 (en) * 2005-02-15 2011-08-04 Children's Hospital, Inc. New live virus vaccines
WO2008024844A2 (en) * 2006-08-22 2008-02-28 The Johns Hopkins University Anticancer combination therapies
US9085638B2 (en) 2007-03-07 2015-07-21 The Johns Hopkins University DNA vaccine enhancement with MHC class II activators
US20080260765A1 (en) * 2007-03-15 2008-10-23 Johns Hopkins University HPV DNA Vaccines and Methods of Use Thereof
US20090285861A1 (en) * 2008-04-17 2009-11-19 Tzyy-Choou Wu Tumor cell-based cancer immunotherapeutic compositions and methods
CA2793959C (en) 2010-03-25 2019-06-04 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
PT2691530T (pt) 2011-06-10 2018-05-10 Univ Oregon Health & Science Glicoproteínas e vectores recombinantes cmv
EP2568289A3 (en) 2011-09-12 2013-04-03 International AIDS Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
EP2586461A1 (en) 2011-10-27 2013-05-01 Christopher L. Parks Viral particles derived from an enveloped virus
ES2631608T3 (es) 2012-06-27 2017-09-01 International Aids Vaccine Initiative Variante de la glicoproteína Env del VIH-1
US20150065381A1 (en) 2013-09-05 2015-03-05 International Aids Vaccine Initiative Methods of identifying novel hiv-1 immunogens
EP2873423B1 (en) 2013-10-07 2017-05-31 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
US9931394B2 (en) 2015-03-23 2018-04-03 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
US11559504B2 (en) * 2017-06-02 2023-01-24 The Penn State Research Foundation Ceramide nanoliposomes, compositions and methods of using for immunotherapy

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5045320A (en) * 1989-03-23 1991-09-03 Medical Biology Institute Large multivalent immunogen
US5399346A (en) * 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
JPH09510211A (ja) * 1994-03-08 1997-10-14 ダナ−ファーバー・キャンサー・インスティテュート Ｔ細胞の不応答性を調節する方法

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021029424A1 (ja) * 2019-08-13 2021-02-18 国立研究開発法人医薬基盤・健康・栄養研究所 免疫記憶に基づく新規疾患治療および予防
JPWO2021029424A1 (enExample) * 2019-08-13 2021-02-18

Also Published As

Publication number Publication date
AU724546B2 (en) 2000-09-28
US5951975A (en) 1999-09-14
AU3390097A (en) 1998-01-21
EP1007087A1 (en) 2000-06-14
CA2258840A1 (en) 1998-01-08
IL127661A (en) 2001-11-25
WO1998000163A1 (en) 1998-01-08
IL127661A0 (en) 1999-10-28

Similar Documents

Publication Publication Date Title
JP2001524928A (ja) クロスプライミング免疫による天然抗原に特異性を有するｃｔｌの誘導
JP5127224B2 (ja) 予防又は治療目的のためのｍｈｃクラスｉ拘束性エピトープに対する免疫応答を誘発し、増強し、維持する方法
Chen et al. Experimental vaccine strategies for cancer immunotherapy
WO1998000163A9 (en) INDUCTION OF CTLs SPECIFIC FOR NATURAL ANTIGENS BY CROSS-PRIMING IMMUNIZATION
Niethammer et al. An oral DNA vaccine against human carcinoembryonic antigen (CEA) prevents growth and dissemination of Lewis lung carcinoma in CEA transgenic mice
JP2019531090A (ja) 改変されたｖｓｖ−ｇおよびそのワクチン
US20020187131A1 (en) Enhanced antigen delivery and modulation of the immune response therefrom
CA2717854C (en) Allogeneic cancer cell-based immunotherapy
JP2003523398A (ja) 樹状細胞のインビボ活性化によるアジュバント治療
JP2008526763A (ja) 予防又は治療目的のｍｈｃクラスｉ拘束性エピトープに対する免疫応答の誘導、増強及び保持方法
AU716497B2 (en) Stimulation of cell-mediated immune responses by targeted particulate genetic immunization
IL173943A (en) Preventive cancer vaccine based on brother of regulator of imprinted sites molecule (boris)
Park Vaccine strategies utilizing C-type lectin receptors on dendritic cells in vivo
Vangasseri et al. Lipid-protamine-DNA-mediated antigen delivery
CN101072582B (zh) 作为癌症疫苗佐剂的α胸腺肽
WO1999030734A1 (en) Venezuelan equine encephalitis virus vectors expressing tumor-associated antigens to induce cancer immunity
JP2023507347A (ja) ネオエピトープをコードするコンストラクトを使用する核酸ワクチン接種
Nawrath et al. Synergistic effect of a combined DNA and peptide vaccine against gp100 in a malignant melanoma mouse model
US7176186B1 (en) Stimulation of cell-mediated immune responses by targeted particulate genetic immunization
JP2001501220A (ja) オンコジーン産物および外来ｍｈｃ分子を用いる癌治療
Jang et al. Simultaneous expression of allogenic class II MHC and B7. 1 (CD80) molecules in A20 B-lymphoma cell line enhances tumor immunogenicity
JP4459060B2 (ja) ポリヌクレオチドからなるワクチン
Gadhave et al. DNA vaccines: A hope full ray in Immunology
JPWO2020260897A5 (enExample)
JPWO2021005339A5 (enExample)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20040616

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20040616

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080115

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20080411

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20080526

A313 Final decision of rejection without a dissenting response from the applicant

Free format text: JAPANESE INTERMEDIATE CODE: A313

Effective date: 20080902

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20081111